Impact of White-Coat Hypertension on Microvascular Complications in Type 2 Diabetes

**Caroline K. Kramer, MD**
**Cristiane B. Leitão, MD, PhD**
**Luís H. Canani, MD, PhD**
**Jorge L. Gross, MD, PhD**

**OBJECTIVE** — The purpose of this study was to determine the impact of white-coat hypertension (WCH) on microvascular complications in type 2 diabetes.

**RESEARCH DESIGN AND METHODS** — A cross-sectional study was conducted in normotensive patients and patients with WCH selected from a cohort of 319 type 2 diabetic patients. Normotension was defined by office blood pressure <140/90 mmHg and daytime blood pressure <135/85 mmHg on ambulatory blood pressure monitoring (ABPM). WCH was defined as office blood pressure ≥140/90 mmHg and daytime blood pressure <135/85 mmHg on ABPM. Subjects were evaluated for diabetic nephropathy (24-h urinary albumin excretion rate) and diabetic retinopathy (classified according to the Global Diabetic Retinopathy Group).

**RESULTS** — Forty-six type 2 diabetic patients had WCH (14.4%; mean age 56.6 years; 45.3% men) and 117 had normotension (36.6%; mean age 55.8 years; 37.5% men). These groups did not differ in clinical and main laboratory characteristics. Systolic ABPM (24-h: 124.7 ± 6.7 vs. 121.0 ± 8.5 mmHg, P = 0.01 and daytime: 126.6 ± 7.2 vs. 123.2 ± 8.2 mmHg, P = 0.01) and blood pressure loads were higher in subjects with WCH than in the normotensive subjects. WCH was associated with an increased risk for macroalbuminuria (odds ratio 4.9 [95% CI 1.3–18.7], P = 0.01). On multivariate analysis models, WCH was associated with macroalbuminuria (2.0 [1.3–3.2], P = 0.02) and increased the risk for both nonproliferative and proliferative diabetic retinopathy (2.7 [1.2–6.6], P = 0.02 for any degree of diabetic retinopathy) after adjustments for confounding factors.

**CONCLUSIONS** — Type 2 diabetic patients with WCH have an increased risk for diabetic retinopathy and diabetic nephropathy. Therefore, WCH should not be considered a harmless condition, and treatment should be considered.
ing the left arm and with the patient in a sitting position, after a 5-min rest, on the same day as the ABPM. ABPM was obtained by oscillimetry (Spacelabs 90207 serial nos. 207/024751 and 207/038016 with calibration certification), with a 15-min interval in the daytime and 20-min interval in the nighttime period. ABPM was performed on an ordinary workday, and patients were advised to maintain their usual daily activities. Sleep time was recorded as the period between the time when the patient went to bed and the time when the patient woke up the next morning. The means of 24-h, daytime, and nighttime systolic and diastolic blood pressure were recorded, as well as systolic and diastolic blood pressure loads (percentage of 24-h and daytime blood pressure ≥140/90 mmHg and nighttime blood pressure ≥120/80 mmHg) and pulse pressure (systolic minus diastolic blood pressure). The difference between the office systolic blood pressure and daytime systolic blood pressure means was included in the analysis and described as the “white-coat effect.”

Blood pressure was evaluated during exercise in a subset of patients (normotension n = 38 and WCH n = 18) by an exercise treadmill test (standard Bruce protocol using a computerized database) (8). Midway through each stage of the exercise protocol, at peak exercise and at 1, 2, and 4 minutes after cessation of exercise, data on symptoms, heart rate and exercise, data on symptoms, heart rate and estimated workload (based on standards tables) in METs (1 MET = 3.5 ml of oxygen uptake per kg body weight per min) were collected. The blood pressure increment was defined as the difference between the peak exercise blood pressure and resting blood pressure.

**Laboratory methods**

The urinary albumin excretion rate (UAER) was measured (values expressed in micrograms per minute) by immunoturbidimetry (MicroAlb Sera-Pak immunoluminometric [Bayer, Tarrytown, NY] on a Cobas Mira Plus analyzer [Roche]; mean intra-assay and interassay coefficients of variation of 4.5 and 7.6%, respectively) in at least two 24-h collections over the preceding 6 months (9). A1C was measured by a high-performance liquid chromatography system (reference range 4.7–6.0%) (Merck-Hitachi 9100; Merck, Darmstadt, Germany). Fasting plasma glucose was measured by the glucose-peroxidase colorimetric enzymatic method (Biodiagnostics). Serum creatinine was measured by the Jaffe method, serum total cholesterol and triglycerides were measured by enzymatic-colorimetric methods (Merck Diagnostica, Darmstadt, Germany; Boeringer Mannheim, Buenos Aires, Argentina), and HDL cholesterol was measured by the homogeneous direct method (ADVIA 1650 AutoAnalyzer). LDL cholesterol was calculated using the Friedenwald formula.

**Outcomes**

**Diabetic retinopathy.** Fundus eye examination was performed by an experienced ophthalmologist after mydriasis, and diabetic retinopathy was classified using the scale developed by the Global Diabetic Retinopathy Group (10). The diabetic retinopathy level was based on the most severe degree of retinopathy in the worst eye affected.

**Diabetic nephropathy.** UAER was measured in 24-h sterile urine samples. Patients were classified, according to UAER, into three groups: normoalbuminuric (UAER <20 µg/min), microalbuminuric (UAER 20–199 µg/min), and macroalbuminuric (UAER ≥200 µg/min). The glomerular filtration rate was estimated using the formula of the Modification of Diet in Renal Disease study: 186 × ([serum creatinine]⁻¹.154 × (age)⁻⁰.²⁰³ × (0.⁷⁴², if female) × (1.₂₁₀, if African descendant)] (11).

**Statistical analysis**

All analyses were performed using the statistical package SPSS (version 14.0; SPSS, Chicago, IL). Data are expressed as means ± SD, except for UAER, triglycerides, blood pressure loads, and white-coat effect values, which are median (interquartile range). Quantitative variables without a normal distribution were log-transformed. Student’s t test or χ² tests were used to compare clinical and laboratory data. Pearson’s test was used to study correlations among clinical variables. Multiple linear regressions were performed with UAER as the dependent variable. Macroalbuminuria, microalbuminuria, and diabetic retinopathy were analyzed as dependent variables in separate models of logistic regression. P < 0.05 (two-tailed) on the univariate analysis was considered significant.

**RESULTS**

WCH was found in 46 (14.4%; mean age 56.6 years; 45.3% men) and normotension in 117 (36.6%; mean age 55.8 years; 37.5% men) type 2 diabetic patients of the overall cohort. These groups were not different regarding age, diabetes duration, anthropometric characteristics, renal function, glycemic control, or lipid profile (Table 1). Interestingly, there were more active smokers among the normotensive patients than among the patients with WCH.

The 24-h systolic blood pressure means on ABPM were higher in the WCH group than in the normotensive group.

**Table 1—Clinical and laboratory characteristics according to blood pressure classification**

|                         | Normotension | White-coat hypertension | P value |
|-------------------------|--------------|-------------------------|---------|
| n                       | 117          | 46                      |         |
| Male subjects           | 53 (45.3)    | 17 (37.5)               | 0.38    |
| Age (years)             | 56.6 ± 10.2  | 55.8 ± 9.6              | 0.65    |
| Diabetes duration (years)| 9.8 ± 7.9    | 10.9 ± 7.0              | 0.38    |
| BMI (kg/m²)             | 28.2 ± 5.0   | 28.8 ± 5.2              | 0.55    |
| Waist circumference (cm)| 97.7 ± 11.1  | 98.0 ± 12.5             | 0.62    |
| Smoking habit           | 25 (21.6)    | 4 (8.9)                 | 0.004   |
| A1C (%)                 | 6.9 ± 1.8    | 7.1 ± 1.8               | 0.61    |
| Fasting plasma glucose (mg/dl)| 159.4 ± 70.5 | 155.2 ± 57.0 | 0.73    |
| Total cholesterol (mg/dl)| 191.3 ± 39.4 | 194.0 ± 48.2 | 0.73    |
| HDL (mg/dl)             | 48.2 ± 13.1  | 47.8 ± 10.1             | 0.87    |
| LDL (mg/dl)             | 112.9 ± 33.1 | 114.0 ± 39.0            | 0.86    |
| Triglycerides (mg/dl)*  | 122 (102)    | 121 (140)               | 0.86    |
| Creatinine (mg/dl)      | 0.85 ± 0.2   | 0.82 ± 0.1              | 0.33    |
| Estimated glomerular filtration rate (ml/min per 1.73 m²)| 90.8 ± 24.4 | 92.9 ± 23.9 | 0.63    |

Data are n (%) or means ± SD unless otherwise indicated. *Median interquartile range.
(124.7 ± 6.7 vs. 121.0 ± 8.5 mmHg, P = 0.01). Daytime systolic blood pressure (126.6 ± 7.2 vs. 123.2 ± 8.2 mmHg, P = 0.01), pulse pressure (24 h: 52 ± 8.1 vs. 48.6 ± 7.6 mmHg, P = 0.01 and daytime 51.7 ± 8.2 vs. 48.8 ± 8.8 mmHg, P = 0.05), and all blood pressure loads (24 h, daytime, and nighttime) followed the same pattern (Table 2).

**Table 2—Blood pressure characteristics according to blood pressure classification**

|                          | Normotension       | White-coat hypertension | P value |
|--------------------------|--------------------|-------------------------|---------|
| n                        | 117                | 46                      |         |
| **Office**               |                    |                         |         |
| Systolic blood pressure  | 123.5 ± 10.8       | 149.7 ± 11.7            | NA      |
| Diastolic blood pressure | 75.9 ± 7.3         | 88.5 ± 9.2              | NA      |
| Pulse pressure           | 47.5 ± 9.2         | 61.1 ± 13.8             | <0.001  |
| **24 h**                 |                    |                         |         |
| Systolic blood pressure  | 121.0 ± 8.5        | 124.7 ± 6.7             | 0.01    |
| Diastolic blood pressure | 72.4 ± 6.0         | 72.7 ± 6.2              | 0.76    |
| Pulse pressure           | 48.6 ± 7.6         | 52 ± 8.1                | 0.01    |
| Systolic blood pressure load (%) | 11.9 (24.2) | 22.2 (21)              | 0.01    |
| Diastolic blood pressure load (%) | 3.3 (8.7)      | 6.3 (12.3)             | 0.03    |
| **Daytime**              |                    |                         |         |
| Systolic blood pressure  | 123.2 ± 8.2        | 126.6 ± 7.2             | 0.01    |
| Diastolic blood pressure | 74.8 ± 6.4         | 74.8 ± 7.0              | 0.97    |
| Pulse pressure           | 48.8 ± 8.8         | 51.7 ± 8.2              | 0.05    |
| Systolic blood pressure load (%) | 5.3 (13.2)        | 12.5 (19.3)            | 0.01    |
| Diastolic blood pressure load (%) | 2.3 (7.3)      | 4.5 (9.4)              | 0.04    |
| **Nighttime**            |                    |                         |         |
| Systolic blood pressure  | 116.6 ± 11.8       | 119.8 ± 9.5             | 0.07    |
| Diastolic blood pressure | 66.8 ± 7.6         | 67.9 ± 7.3              | 0.39    |
| Pulse pressure           | 49.7 ± 8.6         | 51.9 ± 9.5              | 0.17    |
| Systolic blood pressure load (%) | 27.6 (64)       | 46.2 (34.4)            | 0.02    |
| Diastolic blood pressure load (%) | 2 (13.5)      | 6.7 (17.3)             | 0.06    |

Data are means ± SD or median (interquartile range).

Similarly, a higher prevalence of diabetic retinopathy was found in patients with WCH than in normotensive patients (57.9 vs. 34.4%, P = 0.01). The presence of WCH increased the risk for both nonproliferative and proliferative diabetic retinopathy (Fig. 1). Moreover, WCH increased by 2.7-fold (95% CI 1.2–6.6) the chance for any degree of diabetic retinopathy after adjustment for diabetes duration and A1C (P = 0.02). Including current smoking habit in the multivariate regression models (for both UAER and diabetic retinopathy as outcomes) did not materially change the results.

**The white-coat effect and microvascular complications**

To evaluate whether the magnitude of WCH was associated with UAER, the difference between the office systolic blood pressure and daytime systolic blood pressure means (white-coat effect) was calculated. There was a correlation between this variable and UAER (r = 0.325, P = 0.04). In addition, in the linear regression model, the white-coat effect was associated with UAER independently of diabetes duration and A1C value (standardized β-coefficient 0.197, P = 0.03). In addition, patients with proliferative diabetic retinopathy (n = 26) presented with higher white-coat effect values (median 13 [interquartile range 26] mm Hg) than those without diabetic retinopathy or nonproliferative diabetic retinopathy (3 [21] mmHg, P = 0.04).

**WCH and response to exercise**

Thirty-eight normotensive patients and 18 patients with WCH performed exercise testing. The WCH group reached higher blood pressure maximum levels (systolic 183.7 ± 22.2 vs. 166.8 ± 16.1 mmHg, P = 0.002; diastolic 81.5 ± 7.3 vs. 76.4 ± 8.1 mmHg, P = 0.02) than the normotensive group. METs and peak exercise heart rate were similar between the

![Figure 1—WCH OR for type 2 diabetes chronic complications.](Image)
groups, demonstrating equivalent effort during the test (Table 3).

**CONCLUSIONS** — In this sample of type 2 diabetic subjects, the prevalence of WCH was 14%. The clinical and laboratory characteristics of these subjects did not differ from those of the normotensive group, but higher blood pressure levels were demonstrated during both the ABPM and exercise test. The presence of WCH increased the risk for diabetic retinopathy and macroalbuminuria by 2.7 and 2.6 times, respectively, after adjustment for confounders. In addition, the white-coat effect was positively correlated with UAER and also associated with proliferative diabetic retinopathy.

WCH is a common finding in both the hypertensive and general population, being described in 21–30 and 12%, respectively (5,12–14). The prevalence of WCH was believed to be increased in patients with diabetes, reaching up to 74% in hypertensive type 1 diabetic patients (15) and 51% in hypertensive type 2 diabetic patients (16). Subsequently, these findings were challenged in type 2 diabetic patients. Nielsen et al. (17) found a WCH prevalence of 23% in normoalbuminuric individuals, 8% in microalbuminuric patients, and 9% in macroalbuminuric patients. The overall prevalence of 14% in type 2 diabetic patients of this study is the same as that found in the general population and is close to the data of Nielsen et al. (17).

Differences concerning the definition of WCH (systolic/diastolic 24-h blood pressure means or daytime systolic/diastolic blood pressure means) may have contributed to some of the disparities between the studies. Moreover, the prevalence of WCH changes according to age, sex, and ethnicity.

WCH has been historically treated as a benign phenomenon, as previous studies have demonstrated a lower risk for adverse events in this group than in those with sustained hypertension (18,19). This concept has been questioned lately, as WCH has come to be associated with greater left ventricular hypertrophy (5) and cardiovascular mortality (12,20). In the general population, some studies have shown similar clinical characteristics in individuals with WCH and normotensive individuals (22), whereas others have described a higher cardiovascular risk profile in subjects with WCH (23,24). Of interest is the fact that the current smoking habit was more frequent in the normotensive group. This could reflect a lifestyle change in subjects considered to be sicker, because they have increased levels in the office. However, in analysis of other vascular risk factors, such as dyslipidemia, obesity, glycemic control, and abdominal circumference, no difference was observed between groups. Even in the absence of a worse risk profile, WCH was associated with diabetic retinopathy and diabetic nephropathy. To the best of our knowledge, this is the first study to report an association between WCH and microvascular complications in type 2 diabetic patients.

The higher blood pressure peak demonstrated during the exercise test could be one example of how blood pressure responds to daily stressors in subjects with WCH. The WCH phenomenon may indeed reflect an abnormal and vigorous sympathetic response to environmental stimuli, which can be in the form of either mild physical activity or the presence of a health care professional. This acute rise in blood pressure levels could lead to glomerular and retinal damage. Patel et al. (25) demonstrated increased retinal flow after a rise in blood pressure in diabetic patients, suggesting that acute changes in blood pressure have a deleterious impact on retinal vessels. It is worth noting that all of the blood pressure loads in patients with WCH in our sample were higher than those in the normotensive individuals, suggesting acute and repeated rises in blood pressure levels, several times in the course of 24 h, during ordinary activities and probably also exercise.

The limitation of this report is mainly the cross-sectional design, which prevents the drawing of conclusions about the cause-and-effect relationship between WCH and the renal and retinal outcomes. However, this limitation does not detract from the main result of this study.

In summary, type 2 diabetic patients with WCH have an increased risk for microvascular complications. These findings indicate that WCH is not a benign situation in type 2 diabetic patients and most likely represents a phenotype intermediary between normotension and hypertension. Randomized controlled trials are needed to clarify the role of treatment of WCH in preventing type 2 diabetes-associated complications.

Acknowledgments — This study was partially supported by Projeto de Núcleos de Excelência do Ministério de Ciência e Tecnologia, Conselho Nacional de Desenvolvimento Científico e Tecnológico, and Fundo de Incentivo a Pesquisa de Hospital de Clínicas de Porto Alegre.

**References**

1. Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR: Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetics: a prospective observational study (UKPDS 75). Diabetologia 49:1761–1769, 2006

2. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38: UK Prospective Diabetes Study Group. BMJ 317:703–713, 1998

3. Leitao CB, Canani LH, Bolson PB, Molon MP, Pinotti AF, Gross JL: Urinary albumin excretion rate is associated with increased ambulatory blood pressure in normoalbuminuric type 2 diabetic patients. Diabetes Care 28:1724–1729, 2005

4. Leitao CB, Canani LH, Kramer CK, Boza JC, Pinotti AF, Gross JL: Masked hypertension, urinary albumin excretion rate, and echocardiographic parameters in putatively normotensive type 2 diabetic patients. Diabetes Care 30:1255–1260,
2007
5. Sega R, Trocino G, Lanzarotti A, Carugo S, Cesana G, Schiavina R, Valagussa F, Bombelli M, Giannattasio C, Zanchetti A, Mancia G: Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: data from the general population (Pressione Arteriosa Monitorate E Loro Associazioni [PAMELA] study). Circulation 104:1385–1392, 2001
6. Flores L, Gimenez M, Esmatjes E: Prognostic significance of the white coat hypertension in patients with type 1 diabetes mellitus. Diabetes Res Clin Pract 74:21–25, 2006
7. Canani LH, Gerchman F, Gross JL: Increased familial history of arterial hypertension, coronary heart disease, and renal disease in Brazilian type 2 diabetic patients with diabetic nephropathy. Diabetes Care 21:1545–1550, 1998
8. Fletcher GF, Balady G, Froelicher VF, Hartley LH, Haskell WL, Pollock ML: Exercise standards: a statement for healthcare professionals from the American Heart Association. Circulation 91:580–615, 1995
9. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T: Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 28:164–176, 2005
10. Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT: Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110:1677–1682, 2003
11. Levey AS, Coresh J, Falk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G: National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139:137–147, 2003
12. Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, Matsuoka M, Hashimoto J, Hoshi H, Araki T, Tsuji I, Satoh H, Hisamichi S, Imai Y: Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens 20:2183–2189, 2002
13. Pierdomenico SD, Mezzetti A, Lapenna D, Guglielmi MD, Mancini M, Salvatore L, Antidormi T, Costantini F, Cuccurullo F: ‘White-coat’ hypertension in patients with newly diagnosed hypertension: evaluation of prevalence by ambulatory monitoring and impact on cost of health care. Eur Heart J 16:692–697, 1995
14. III Guidelines for the Use of Ambulatory Blood Pressure Monitoring—ambulatory monitoring of blood pressure. Sociedade Brasileira de Hipertensao. Arq Bras Cardiol 77:384–389, 2001
15. Flores L, Recasens M, Gomis R, Esmatjes E: White coat hypertension in type 1 diabetic patients without nephropathy. Am J Hypertens 13:560–563, 2000
16. Puig JG, Rulope LM, Ortega R: Antihypertensive treatment efficacy in type II diabetes mellitus: Dissociation between casual and 24-hour ambulatory blood pressure. Spanish Multicenter Study Group. Hypertension 26:1093–1099, 1995
17. Nielsen FS, Gaede P, Vedel P, Pedersen O, Parving HH: White coat hypertension in NIDDM patients with and without incipient and overt diabetic nephropathy. Diabetes Care 20:850–863, 1997
18. Khattar RS, Swales JD, Banfield A, Dore C, Senior R, Lahiri A: Prediction of coronary and cerebrovascular morbidity and mortality by direct continuous ambulatory blood pressure monitoring in essential hypertension. Circulation 100:1071–1076, 1999
19. Kario K, Shimada K, Schwartz JE, Matsuo T, Hoshide S, Pickering TG: Silent and clinically overt stroke in older Japanese subjects with white-coat and sustained hypertension. J Am Coll Cardiol 38:238–245, 2001
20. Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, Mancia G: Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 111:1777–1783, 2005
21. Chrysant SG: Treatment of white coat hypertension. Curr Hypertens Rep 2:412–417, 2000
22. Pierdomenico SD, Lapenna D, Guglielmi MD, Antidormi T, Schiavone C, Cuccurullo F, Mezzetti A: Target organ status and serum lipids in patients with white coat hypertension. Hypertension 26:801–807, 1995
23. Muldoon MF, Nazzaro P, Sutton-Tyrrell K, Manuck SB: White-coat hypertension and carotid artery atherosclerosis: a matching study. Arch Intern Med 160:1507–1512, 2000
24. Julius S, Mejia A, Jones K, Krause L, Schork N, van de Ven C, Johnson E, Petrin J, Sekkarie MA, Kjeldsen SE, et al.: “White coat” versus “sustained” borderline hypertension in Tecumseh, Michigan. Hypertension 16:617–623, 1990
25. Rassam SM, Patel V, Kohn EM: The effect of experimental hypertension on retinal vascular autoregulation in humans: a mechanism for the progression of diabetic retinopathy. Exp Physiol 80:53–68, 1995